Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

The WHO classification of MDS does make a difference.

Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellström-Lindberg E.

Blood. 2004 May 1;103(9):3265-70. Epub 2003 Dec 18.

2.

Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.

Navarro I, Ruiz MA, Cabello A, Collado R, Ferrer R, Hueso J, Martinez J, Miguel A, Orero MT, Pérez P, Nolasco A, Carbonell F.

Leuk Res. 2006 Aug;30(8):971-7. Epub 2006 Jan 19.

PMID:
16423393
3.

Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.

Germing U, Strupp C, Kuendgen A, Isa S, Knipp S, Hildebrandt B, Giagounidis A, Aul C, Gattermann N, Haas R.

Haematologica. 2006 Dec;91(12):1596-604.

4.

Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.

Hellström-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Kanter-Lewensohn L, Linder O, Luthman M, Löfvenberg E, Nilsson-Ehle H, Samuelsson J, Tangen JM, Winqvist I, Oberg G, Osterborg A, Ost A.

Blood. 1998 Jul 1;92(1):68-75.

5.

Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.

Balleari E, Rossi E, Clavio M, Congiu A, Gobbi M, Grosso M, Secondo V, Spriano M, Timitilli S, Ghio R.

Ann Hematol. 2006 Mar;85(3):174-80. Epub 2006 Jan 12.

PMID:
16408206
6.

The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: a single institution experience from Turkey.

Demirkan F, Alacacioglu I, Piskin O, Ozsan HG, Akinci B, Ozcan AM, Yavuzsen T, Yuksel E, Undar B.

Leuk Lymphoma. 2007 Jul;48(7):1372-8.

PMID:
17613766
7.

[Re-evaluation of classification of myelodysplastic syndromes with low percentage bone marrow blasts].

Yu MH, Xu ZF, Li L, Nie L, Liu L, Zhang Y, Qin TJ, Hao YS, Xiao ZJ.

Zhonghua Xue Ye Xue Za Zhi. 2009 Jan;30(1):3-7. Chinese.

PMID:
19563026
8.

Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodyplastic syndromes.

Breccia M, Carmosino I, Biondo F, Mancini M, Russo E, Latagliata R, Alimena G.

Leuk Res. 2006 Feb;30(2):178-82. Epub 2005 Aug 15.

PMID:
16102825
9.

Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.

Remacha AF, Arrizabalaga B, Villegas A, Manteiga R, Calvo T, Julià A, Fernández Fuertes I, González FA, Font L, Juncà J, del Arco A, Malcorra JJ, Equiza EP, de Mendiguren BP, Romero M.

Haematologica. 1999 Dec;84(12):1058-64.

10.
11.
12.
13.

Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.

Jädersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellström-Lindberg E.

Blood. 2005 Aug 1;106(3):803-11. Epub 2005 Apr 19.

14.

Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications.

Lorand-Metze I, Pinheiro MP, Ribeiro E, de Paula EV, Metze K.

Leuk Res. 2004 Jun;28(6):587-94.

PMID:
15120935
15.

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.

Hellström-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, Grimfors G, Hesse-Sundin E, Hjorth M, Kanter-Lewensohn L, Linder O, Luthman M, Löfvenberg E, Oberg G, Porwit-MacDonald A, Rådlund A, Samuelsson J, Tangen JM, Winquist I, Wisloff F; Scandinavian MDS Group.

Br J Haematol. 2003 Mar;120(6):1037-46.

PMID:
12648074
16.
17.

Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.

Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J.

Transfusion. 2010 Jan;50(1):190-9. doi: 10.1111/j.1537-2995.2009.02361.x. Epub 2009 Aug 28.

PMID:
19719471
18.

Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts.

Font P, Loscertales J, Soto C, Ricard P, Novas CM, Martín-Clavero E, López-Rubio M, Garcia-Alonso L, Callejas M, Bermejo A, Benavente C, Ballesteros M, Cedena T, Calbacho M, Urbina R, Villarrubia J, Gil S, Bellón JM, Diez-Martin JL, Villegas A.

Ann Hematol. 2015 Apr;94(4):565-73. doi: 10.1007/s00277-014-2252-4. Epub 2014 Nov 13.

PMID:
25387664
19.
20.

Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.

van de Loosdrecht AA, Westers TM, Westra AH, Dräger AM, van der Velden VH, Ossenkoppele GJ.

Blood. 2008 Feb 1;111(3):1067-77. Epub 2007 Oct 30.

Supplemental Content

Support Center